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Summary
Background: Subclinical myocyte injury plays an important role in the progression of
congestive heart failure. However, the clinical and hemodynamic factors that inﬂu-
ence the concentrations of biomarkers of myocyte injury have not been clariﬁed.
Methods: Blood was sampled during diagnostic cardiac catheterization from 108
consecutive patients without acute coronary syndrome and acute cardiac decom-
pensation. The serum concentrations of B-type natriuretic peptide (BNP), cardiac
troponin I (cTnI), creatine kinase (CK)-MB, and myoglobin were measured simulta-
neously by high sensitive PATHFAST assay. Single and multiple variable regression
analyses were carried out in search of correlations between clinical and hemody-
namic variables and concentrations of biomarkers.
Results: By multiple variable analysis, hemoglobin concentration, pulmonary capil-
lary wedge pressure (PCWP), left ventricular (LV) ejection fraction, and estimated
glomerular ﬁltration rate (GFR) were independently correlated with a BNP con-
centration ≥median 72.1 pg/ml. The only factors independently correlated with a
concentration of cTnI ≥median 0.01 ng/ml were PCWP and estimated GFR. Cardiac
index emerged as a single, powerful, independent correlate of CK-MB concentration
≥median 0.66 ng/ml, and estimated GFR emerged as a single independent correlate
of myoglobin concentration ≥median 40.1 ng/ml.
∗ Corresponding author. Tel.: +81 6 6482 1521; fax: +81 6 6482 7430.
E-mail address: cardioys@kuhp.kyoto-u.ac.jp (Y. Sato).
0914-5087/$ — see front matter © 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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Conclusions: Clinical and hemodynamic factors inﬂuence the concentrations of BNP,
cTnI, CK-MB, and myoglobin. These factors should be considered when interpreting
the concentrations of these biochemical markers.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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sheath just before the cardiac catheteriza-
tion, and the concentrations of BNP, cTnI,
CK-MB, and myoglobin were immediately
measured simultaneously by rapid assay PATH-
FAST [18] (Mitsubishi Chemical, Tokyo, Japan;
http://www.pathfast.de/pathfast.html?L=1),
which fulﬁll the criteria that coefﬁcient variation
Table 1 Characteristics of 108 study patients
Age (years) 67.0± 11.4
Men, n (%) 63/108 (58)
Presence of ≥75%
coronary stenosis, n (%)
44/108 (41)
Presence of atrial
ﬁbrillation, n (%)
17/108 (16)
Body mass index
(kg/m2)
23.2± 3.5
(12.1—33.3)
Hemoglobin (g/dl) 12.9± 2.0
(6.8—17.3)
Estimated glomerular
ﬁltration rate (ml/min)
59.7± 18.4
(20—99)
Pulmonary capillary
wedge pressure
(mmHg)
8.8± 5.2 (2—31)
Cardiac index
(l/(minm2))
3.24± 0.83
(1.69—6.29)
Left ventricular
ejection fraction (%)
60.0± 16.1
(12—84)
B-type natriuretic
peptide (pg/ml)
163.7± 228.3
(2.0—1216.0)
Cardiac troponin I
(ng/ml)
0.023± 0.029
(0.00—0.15)
Creatine kinase-MB 0.82± 0.63© 2008 Japanese Colleg
reserved.
ntroduction
edical history, physical examination, chest radio-
raphy and measurement of left ventricular (LV)
unction are the main means of evaluation and diag-
osis of congestive heart failure (HF). However,
diagnosis of HF based on physical examina-
ion might be challenging, while other modes of
ssessment of LV function may not be rapidly
vailable routinely. On the other hand, the mea-
urements of biomarkers are expeditious and are
ot inﬂuenced by inter-observer variability. The
deal biomarker reﬂects the pathogenic process,
hould be diagnostically and prognostically reliable,
nd should be useful for the monitoring of therapy
1—5].
Since subclinical myocyte injury plays an impor-
ant role in the progression of compensated and
ecompensated HF, efforts are being made to ﬁnd
biomarker that reﬂects myocyte injury [1,6,7].
mong multiple candidates [8], including crea-
ine kinase (CK)-MB, myoglobin, and heart type
atty acid binding protein, both cardiac troponin T
cTnT) and cardiac troponin I (cTnI) have emerged
s powerful prognostic factors [1,9—12]. A strat-
gy combining measurements of BNP, a marker of
yocardial load, and cTnT or cTnI, markers of
yocyte injury, has been proposed in the setting
f compensated and decompensated congestive HF
ith a view to identify patients at the highest risk
1,8,11—17]. However, the clinical and hemody-
amic factors that inﬂuence the concentrations of
iomarkers of myocyte injury have not been clari-
ed.
ethods
tudy population
his study included 108 consecutive patients who,
etween April and July 2005, underwent diagnostic
ight and left heart cardiac catheterization, includ-
ng left ventriculography and coronary angiography.
heir clinical characteristics are shown in Table 1.
ince myocardial ischemia elevates the concen-
rations of BNP, cTnI, CK-MB, and myoglobin, we
xcluded the patients who had a history of per-
utaneous coronary intervention or acute coronaryyndrome within 1 month. Patients who had a
istory of acutely decompensated HF within 1
onth underwent cardiac catheterization after
he stabilization of HF. Patients treated with
emodialysis were excluded from the study. The
tudy procedures were in compliance with the
uidelines of the Hyogo Prefectural Amagasaki Hos-
ital.
lood sampling and processing
enous blood was drawn from the femoralfraction (ng/ml) (0.13—4.30)
Myoglobin (ng/ml) 49.1± 31.1
(13.7—226.0)
Unless speciﬁed otherwise, values are means± S.D. (range).
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Table 2 P values and odds ratio of single variable analysis
BNP≥ 72.1 pg/mla cTnI≥ 0.01 ng/mla CK-MB≥ 0.66 ng/mla Myoglobin≥ 40.1 ng/mla
Age≥ 68.0a P = 0.083 P = 0.153 P = 0.119 P = 0.002
1.97 (0.91—4.25) 1.78 (0.80—3.95) 1.84 (0.85—3.96) 3.40 (1.54—7.53)
Male gender P = 0.033 P = 0.973 P = 0.416 P = 0.720
0.42 (0.19—0.93) 1.01 (0.46—2.23) 1.37 (0.63—2.96) 1.15 (0.53—2.47)
Presence of AF P = 0.023 P = 0.171 P = 0.728 P = 0.856
3.96 (1.20—13.08) 2.07 (0.72—5.89) 1.20 (0.42—3.39) 1.10 (0.39—3.10)
HGB≥ 13.3 g/mla P = 0.0007 P = 0.617 P = 0.852 P = 0.332
0.24 (0.11—0.55) 0.82 (0.37—1.78) 0.93 (0.43—1.98) 0.68 (0.32—1.46)
BMI≥ 23.9 kg/m2a P = 0.408 P = 0.372 P = 0.896 P = 0.020
0.70 (0.31—1.60) 1.45 (0.63—3.33) 1.05 (0.46—2.37) 2.74 (1.16—6.44)
PCWP≥ 8.0mmHga P = 0.0002 P = 0.011 P = 0.042 P = 0.925
4.65 (2.04—10.44) 2.89 (1.27—6.57) 2.26 (1.02—4.82) 1.03 (0.48—2.21)
CI≥ 3.15 (l/(minm2))a P = 0.055 P = 0.166 P < 0.0001 P = 0.004
0.47 (0.21—1.01) 0.57 (0.26—1.26) 0.13 (0.05—0.31) 0.31 (0.14—0.70)
LVEF≥ 63.6%a P < 0.0001 P = 0.177 P = 0.333 P = 0.007
0.17 (0.07—0.39) 0.57 (0.26—1.28) 0.68 (0.31—1.47) 0.33 (0.15—0.74)
EGFR≥ 61.0ml/mina P = 0.0003 P = 0.026 P = 0.056 P < 0.0001
0.22 (0.10—0.51) 0.40 (0.18—0.90) 0.47 (0.22—1.02) 0.14 (0.06—0.33)
AF, atrial ﬁbrillation; BMI, body mass index; HGB, hemoglobin; PCWP, pulmonary capillary wedge pressure; CI, cardiac index; LVEF, left ventricular ejection fraction; EGFR, estimated
glomerular ﬁltration rate.
a Median values.
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.iomarkers of myocyte injury in heart failure
CV) at the 99th percentile of a reference control
roup for the assay should be less than 10% [19].
emoglobin and blood creatinine concentrations
ere measured within 14 days before the catheter-
zation. The glomerular ﬁltration rate (GFR) was
stimated by the Cockroft—Gaut equation.
tatistical analysis
ll results are expressed as means± standard devi-
tion (S.D.). Clinical and hemodynamic variables
ere entered in a logistic regression analysis and
dds ratios and 95% conﬁdence intervals were
alculated to identify factors that were corre-
ated with the concentrations of BNP, cTnI, CK-MB,
nd myoglobin. Multiple variable analysis was car-
ied out by entering all single signiﬁcant factors
nto a regression model to determine whether
he clinical and hemodynamic variables were
ndependently correlated with the concentrations
f biomarkers. A P value <0.05 was considered
igniﬁcant.
esults
he outcomes of the single and multiple variable
nalyses showing correlations between biomarkers
nd hemodynamic or clinical variables are listed
n Tables 2 and 3, respectively. In general, age,
he presence of atrial ﬁbrillation, anemia, elevated
edge pressure, low cardiac index, low ejection
raction, and renal insufﬁciency were the factors
hat have a tendency to elevate the concentrations
f BNP, cTnI, CK-MB, and myoglobin. On the other
and, male gender and increased body mass index
ere the mitigating factors for BNP and the increas-
ng factors for the markers of myocyte injury (cTnI,
K-MB, and myoglobin). The presence of coronary
rtery disease was not a signiﬁcant factor that
ffects the concentration of BNP, cTnI, CK-MB, and
yoglobin in this small patient population (data not
hown).
The concentration of BNP was correlated
ith gender, the presence of atrial ﬁbrillation,
emoglobin concentration, pulmonary capillary
edge pressure (PCWP), LV ejection fraction (EF),
nd estimated GFR, in single variable analysis.
y multiple variable analysis, hemoglobin con-
entration, PCWP, LVEF and estimated GFR were
ndependently correlated with the concentration of
NP. When age (as a continuous variable) and the
resence of coronary artery disease were added to
his multivariate model, hemoglobin, PCWP, LVEF,
nd estimated GFR remained signiﬁcant (data not
hown). T
ab
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By contrast, fewer correlations were observed
between demographic clinical and hemodynamic
variables and the concentrations of cTnI, CK-MB, or
myoglobin. PCWP and estimated GFR were corre-
lated with the concentrations of cTnI in both single
and multiple variable analyses. When gender was
added to this model, both PCWP and estimated GFR
remained signiﬁcant (data not shown). In contrast,
when age, gender, and the presence of coronary
artery stenosis were added to this model, esti-
mated GFR became less signiﬁcant [PCWP ≥median
(P = 0.009; OR 3.17; 95% CI 1.31—7.63) and esti-
mated GFR ≥median (P = 0.077; OR 0.46; 95% CI
0.19—1.08)].
PCWP and cardiac index were correlated with
the concentration of CK-MB in the single vari-
able analysis, while cardiac index emerged as a
single powerful independent factor in the mul-
tiple variable analysis. When age, gender and
the presence of coronary artery stenosis were
added to this model, cardiac index remained sig-
niﬁcant (CI≥median: P < 0.0001; OR 0.15; 95% CI
0.06—0.37). The concentration of myoglobin was
correlated with age, body mass index, cardiac
index, LVEF, and estimated GFR in single variable
analysis. However, only estimated GFR remained as
an independent correlate by multiple variable anal-
ysis. When gender and the presence of coronary
artery stenosis were added to the model, estimated
GFR remained signiﬁcant (estimated GFR≥median:
P = 0.0004; OR 0.18; 95% CI 0.07—0.47).
Discussion
Factors that affect the concentrations of
BNP
BNP, a hormone released mainly from the left
ventricle, has multiple effects in congestive
HF, including an increase in GFR, relaxation
of vascular smooth muscle cells, and block-
ade of the sympathetic nervous and rennin—
angiotensin—aldosterone systems [20,21]. BNP is
cleared from the plasma by binding to the natri-
uretic peptide receptor type C, and via proteolysis
by neutral endopeptidases present on the surface
of endothelial cells, smooth muscle cells, car-
diac myocytes, renal epithelium, and ﬁbroblasts
[20,21].
BNP in patients presenting with congestive HF
is measured mainly for the purpose of diagnosis,
prognosis, and therapeutic monitoring [1]. How-
ever, the concentrations of BNP ﬂuctuate according
to the underlying disorder, a factor that should be
considered when interpreting its measurements. An
o
W
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ncrease in LV wall stress [22], age [23], female gen-
er [23], renal dysfunction [24,25], anemia [26],
nd the presence of atrial ﬁbrillation [27] are the
actors that increase the concentrations of BNP,
hile obesity decreases its concentrations [28].
ecently, Tsutamoto et al. reported that when these
actors were included as covariates in a multiple
ariable analysis, gender and the presence of atrial
brillation became non-signiﬁcant, while LVEF, LV
nd-diastolic pressure, hemoglobin concentration
nd estimated GFR remained independently cor-
elated with BNP concentrations [24]. Therefore,
ur observations are concordant with these previ-
us reports, supporting our use of BNP as a standard
gainst which to compare other biochemical mark-
rs, such as cTnI, CK-MB, and myoglobin.
actors that inﬂuence the concentrations of
ardiac troponin I, creatine kinase-MB, and
yoglobin
n general, the factors that inﬂuence the concentra-
ions of cTnI, CK-MB, and myoglobin appear simple
ompared with those observed with BNP in our
tudy. This might be attributable to the fact that,
nlike BNP, cTnI, CK-MB, and myoglobin are not hor-
ones.
Cardiac troponin I: The troponin complex con-
ists of subunits C, I, and T, located on the actin
laments of striated muscle [29,30]. The cardiac
soforms T and I are only expressed in cardiac mus-
le, and both cTnT and cTnI are found as structural
ound proteins, while 6—8% of all cTnT, and approx-
mately 3.5% of all cTnI, are present as a free pool in
he cytosol. Therefore, the release of cTnT or cTnI
nto the circulation is considered to be due to both
eversible and irreversible myocyte injury [29,30].
The clinical and hemodynamic factors that are
orrelated with troponin concentrations have not
een clariﬁed. Our previous analysis of two other
atabases showed no correlation between baseline
oncentrations of cTnT and LVEF [9,31]. Horwich et
l. similarly reported that elevated concentrations
f cTnI were not correlated with baseline LVEF, and
ere weakly correlated with PCWP [11]. To the best
f our knowledge, this is the ﬁrst report conﬁrming
hat PCWP and estimated GFR were independently
orrelated with the concentrations of cTnI.
The mechanism of cTnT and cTnI release
n patients with congestive HF in the absence
f acute coronary syndrome remains unclear.
e and other investigators have hypothe-
ized that myocardial load, activation of the
ennin—angiotensin—aldosterone and autonomous
ympathetic systems, inﬂammation, and subendo-
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Riomarkers of myocyte injury in heart failure
ardial ischemia are the causes of myocyte injury,
n compensated as well as in decompensated
ongestive HF, that release cTnT or cTnI into the
irculation [6,7,31,32]. The mechanisms of cTnT
r cTnI elevation in patients with renal failure are
lso unresolved, although the elevation of cTnT
s a prognostic factor in this clinical setting [33].
everal investigators hypothesized initially that
remia-induced skeletal myopathy might be the
ource for pseudo positive cTnT [34]. However,
ith the recent development of a speciﬁc assay
35], there seem to be insufﬁcient data to sup-
ort a skeletal muscle source as an explanation
or the increase in serum cTn concentrations in
atients with renal failure [30]. Furthermore, a
ecent study found that cTnT is fragmented into
olecules small enough to be excreted by the
idney [36], though both free and bound cTnT are
7 and 77 kDa molecules, respectively, making it
nlikely to be cleared by the kidney. Therefore,
he renal clearance might inﬂuence the serum
oncentrations of cTnT or cTnI. In conclusion,
ur observations support the hypothesis that the
levation in cTnI is inﬂuenced independently by HF
tatus and renal function.
Creatine kinase-MB and myoglobin: CK-MB and
yoglobin are cytosolic enzymes, which are not
inked to the myoﬁbrils, and an increase in their
oncentrations might be due to membrane injury or
o cytosolic leakage. Compared with BNP and cTnT
r cTnI, the number of publications pertaining to
he measurements of CK-MB and myoglobin remains
ery low [37]. We have recently reported a rapid
ncrease in serum concentrations of CK-MB and
yoglobin, compared with cTnI and BNP, in patients
ith acutely decompensated HF in the absence of
cute coronary syndrome [38]. Therefore, this rapid
ise in the concentrations of cytosolic components
ay add information regarding the pathophysiology
f congestive HF, particularly in the decompensated
hase.
CK catalyzes the transfer of a high-energy phos-
hate from ATP to creatine, producing creatine
hosphate [39]. CK and its isoforms are large
olecules which are mainly cleared by the reticulo-
ndothelial system [40]. In animal experiments, CK
as not excreted in the urine, and its concentration
as not inﬂuenced by changes in renal or hepatic
lood ﬂow [39]. On the other hand, since most
keletal muscles contain 1—3% of CK-MB, injury to
keletal muscle can release detectable amounts
f CK-MB. However, further study is necessary to
nvestigate the mechanism of our observation of
he absence of correlation between CK-MB and esti-
ated GFR, versus the presence of a correlation
etween CK-MB and cardiac index.25
Myoglobin, a mobile carrier developed in red
uscle in response to mitochondrial demand,
ransports oxygen from the sarcolemma to the
itochondria of myocytes and red muscle cells
41]. In 1982, Klocke et al. reported that myoglobin
ntering the vascular space was cleared rapidly by
he kidney [42]. This observation is supported by
he powerful independent prediction of myoglobin
oncentration by estimated GFR in this study.
tudy limitations
his study has two notable limitations. First, all
atients were in a compensated state and no
atient suffered from acute HF. During acute
ardiac decompensation, the concentrations of
NP, cTnI, CK-MB, and myoglobin increase, includ-
ng in the absence of acute coronary events.
n our previous study of biomarkers in acute
F, the mean values of BNP, CK-MB, and cTnI,
easured by the same PATHFAST assay, were
ncreased to 854± 548 pg/ml, 2.4± 1.6 ng/ml, and
.063± 0.047 ng/ml, respectively [43]. In a state
f acute decompensation, the impact of myocar-
ial load on myocyte injury might be considerably
reater. Second, while obesity has been reported to
itigate the increase in BNP [28], we found only a
rend toward a negative correlation between body
ass index and concentration of BNP. This may be
xplained by the rarity of obesity in our Asian pop-
lation, with only 4 of 108 patients presenting with
body mass index ≥30 in this study.
cknowledgment
e thank Rodolphe Ruffy, MD (http://www.cardio
cript.com) for editing the manuscript.
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